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Abstract
Purpose—The retinoblastoma tumor suppressor (RB), a key regulator of cell cycle progression 
and proliferation, is functionally suppressed in up to 50% of non-small cell lung cancer (NSCLC). 
RB function is exquisitely controlled by a series of proteins including the CyclinD-CDK4/6 
complex. In the current study, we interrogated the capacity of a CDK4/6 inhibitor, palbociclib, to 
activate RB function.
Experimental Design and Results—We employed multiple isogenic RB proficient and 
deficient NSCLC lines to interrogate the cytostatic and cytotoxic capacity of CDK 4/6 inhibition 
in vitro and in vivo. We demonstrate that while short term exposure to palbociclib induces cellular 
senescence, prolonged exposure results in inhibition of tumor growth. Mechanistically, CDK 4/6 
inhibition induces a pro-apoptotic transcriptional program through suppression of IAPs FOXM1 
and Survivin, while simultaneously augmenting expression of SMAC and Caspase 3 in an RB-
dependent manner.
Conclusions—This study uncovers a novel function of RB activation to induce cellular 
apoptosis through therapeutic administration of a palbociclib and provides a rationale for the 
clinical evaluation of CDK 4/6 inhibitors in the treatment of NSCLC patients.
Keywords
Retinoblastoma Protein; palbociclib; SMAC; Apoptosis and FOXM1
Introduction
Cell cycle progression from G1 to S phase is tightly regulated via phosphorylation of the 
retinoblastoma tumor suppressor (RB) by the CDK4/6-cyclin D complex. It is well 
established that p16 inhibits the catalytic activity of the CDK4/6-cyclin D complex resulting 
in cell cycle arrest. Expression of RB and p16 are inversely correlated across multiple 
cancers; thus RB-positive tumors tend to have low levels of p16 and active CDK4/6-cyclin 
D. Within the context of non-small cell lung cancer (NSCLC) p16 is mutated, deleted, or 
silenced via methylation of CpG islands, in 10-50% of cases, permitting constitutive 
phosphorylation of RB and cell cycle progression (1). p16 function can be mimicked 
pharmacologically using a CDK4/6 inhibitor (2).
Recently, a CDK4/6 specific inhibitor, PD-0332991, palbociclib, was FDA-approved for the 
management of women with breast cancer (2). Clinically, this drug is delivered for the first 
21 days of a 28-day cycle and there are currently over 10 active clinical trials testing 
CDK4/6 inhibitors in patients with NSCLC. Management of NSCLC has been dramatically 
enhanced through targeting unique mutations such as EGFR and ALK (3). We sought to 
elucidate mechanistically the functional consequence of CDK4/6 inhibition on both RB 
proficient and RB deficient NSCLC.
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In this study, we utilized two isogenic RB proficient and deficient NSCLC cell lines. As 
expected, RB activation led to cell cycle arrest and cellular senescence. However, 
surprisingly, in vivo analysis demonstrated that RB activation via CDK 4/6 inhibition 
resulted in apoptosis. Mechanistically, we demonstrate that intact RB represses the 
expression of two inhibitors of apoptosis proteins (IAPs), FOXM1 and Survivin, which 
enable SMAC and cytochrome C to activate cleaved caspase 3 and promote the apoptotic 
pathway. In the absence of functional RB, FOXM1 and Survivin form a protein complex 
with Caspase 3, inhibiting the apoptotic machinery. This novel finding suggests a more 
potent role of CDK4/6 inhibitors in cancer management.
Materials and Methods
Cell Culture
Parental KRAS wild type H1299 and KRAS mutant H460 or A459 cells, were provided by 
Dr. Bo Lu and Dr. Sunday Shoyele (Department of Radiation Oncology and Dept. of 
Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia). 
Cell lines were authenticated by DDS Medical. shCon H1299, shRB H1299, shCon H460, 
shRB H460, shCon and shSMAC cells were maintained in improved minimum essential 
medium (IMEM) supplemented with 10% FBS (heat-inactivated FBS) and maintained at 
37°C in a humidified 5% CO2 incubator.
Genetic modulation of RB or FOXM1 or Survivin/BIRC5 or SMAC in NSCLC Cells with 
Luciferase Expression
Stable Knockdown of RB or FOXM1, or Survivin or SMAC was carried out as previously 
described (4,5). RB deficient lines were generated using retroviral infection, while SMAC, 
FOXM1 and Survivin stable knockdown was performed with lentiviral constructs (Santa 
Cruz, California). shRB, shFOXM1, shSmac and shSurvivin stable polyclonal populations 
were puromycin selected and knockdown was verified using qRT-PCR or immunoblotting as 
previously described (4,5). shRNA nucleotide sequences are provided in Supplemental Table 
1. Further, RB proficient and deficient cells were infected with lentiviral constructs coding 
luciferase and selected using G418 antibiotic (Thermo Fisher Scientific, Waltham, MA).
RNA Analysis
Total RNA was isolated from RB-proficient and RB-deficient H1299 and H460 cells treated 
with PD 0332991 (500 nM) using Trizol reagent (Invitrogen). The concentration and quality 
of RNA was analyzed using a Nanodrop. Total RNA was reverse transcribed and subjected 
to semi-quantitative PCR or real time PCR. Real time PCR was performed with an ABI 
Step-One apparatus using the Power SYBR Green Master Mix. Target mRNA primers for 
RB, PCNA, CycinA, and GAPDH were used. The signals were normalized with an internal 
control GAPDH and quantitated by ΔΔCT values. The primers are presented in the 
supportive information, Supplemental Table 2.
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Human Transcriptome Array Profiling and Identification of E2F Regulated Signatures 
involved in apoptosis signaling
RNA was isolated from RB-proficient H1299 cells after three-week treatment with PD 
0332991 (500 nM). Human transcriptome array (HTA) 2.0 was used and the microarray 
analysis and gene signatures were performed using GeneSpring v14.5 and Ingenuity 
Pathway Analysis software and GSEA were used to identify disease function, senescence 
and apoptosis, RB/E2F gene signatures. Microarray data were deposited at Gene Expression 
Omnibus (GEO): GSE87879 (H1299). Targets were validated via qRT-PCR using SYBR 
Green in StepOne Plus PCR Thermocycler (Applied Biosystems). The signals were 
normalized with respective GAPDH control signals and quantitated using ΔΔCT values, as 
described (5).
Immunoblot Analysis
Briefly, shCon and shRB cells treated with PD 0332991 (500 nM) for three weeks and were 
harvested by trypsinization, and cell lysis was carried out in radio-immunoprecipitation 
assay (RIPA) buffer [(150 mmol/L NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS, 50 
mmol/L Tris (pH, 8.0)] supplemented with protease inhibitors, phosphatase inhibitors, and 
phenyl methylsulfonyl fluoride. After sonication, lysates were clarified, and protein 
concentrations were determined using Bio-Rad Protein Assay Reagent. Protein was 
subjected to SDS-PAGE and transferred onto Immobilin-P PVDF transfer membranes 
(Millipore Corp).
The membranes were immunoblotted for RB (BD Sciences, USA), phospho-RB (phospho-
serine 780), PCNA, CDK4, CDK6, CyclinA, Caspase3, Cleaved caspase3, SMAC, FOXM1, 
Survivin/BIRC5, LaminB and GAPDH (Santa Cruz Inc., USA), p16 antibody from 
Proteintech (USA), Annexin V from GeneTex (Irvine, CA, USA). Protein signals were 
visualized via X-ray film using enhanced Western lightening chemiluminescence (Perkin-
Elmer Life Sciences) and normalized with LaminB or GAPDH loading control.
Co-Immunoprecipitation Assay
Total cell lysates from RB deficient H1299 and H460 cells overexpressing Flag tagged 
human-SMAC (Vigene Biosciences, MD, USA) or human FOXM1 or human Survivin 
cDNA’s from (Origene, Rockville, MD, USA), were immunoprecipitated with either 
FOXM1 or Survivin or SMAC antibody and immunoblotted with FOXM1, Survivin 
(BIRC5), Caspase 3, Cleaved Caspase 3, LaminB, or GAPDH (Santa Cruz Inc., Sigma Inc. 
and Cell Signal). Signals were normalized with LaminB or GAPDH internal controls.
Flow Cytometry Analysis
Cancer cell proliferation assay was performed via BrdU incorporation and coupled with flow 
cytometry analysis as described previously (6,7). RB-proficient and deficient H1299 and 
H460 cells and SMAC overexpressing H1299 and H460 cells treated with either PD 
0332991 or DMSO were pulse-labeled with BrdU for 2 hours prior to harvest. Cells were 
fixed in 75% ethanol, pelleted, re-suspended in 2N HCl + 0.5 mg/mL pepsin, and incubated 
at room temperature for 30 minutes. Sodium tetraborate (0.1 mol/L) was added to neutralize 
2N HCl. The cell pellets were washed with IFA buffer, centrifuged, and then washed with 
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IFA + 0.5% Tween 20 solution. The pellet was resuspended in IFA solution containing FITC 
conjugated anti-BrdU antibody (BD Bioscience), incubated in the dark at room temperature 
for 45 minutes, washed with IFA + 0.5% Tween-20 and pelleted. The pellet was then 
suspended in PBS containing propidium iodide (0.2 μg/μL) and analyzed for BrdU 
incorporation using Beckman Coulter Cell Lab Quanta SC flow cytometer. Flow cytometry 
analysis was performed using FlowJo software (GE Healthcare, Piscataway, NJ, USA).
Cellular Apoptosis and Reactive Oxygen Species (ROS) Measurements
RB proficient and deficient H1299 xenografts and H460 cells were exposed to CDK4/6 
specific inhibitor (PD 0332991) for three weeks (500 nM in in vitro or 150 mg/kg in vivo). 
At the end of the experiment, total lysates were made. The total cell lysates were analyzed 
for apoptosis or cell death using human apoptosis antibody array (Abcam) or cell death 
detection ELISA (Roche) according to the manufacture’s protocol. ROS generation in shCon 
or shRB or or shFOXM1 or shSMAC or Adeno Flag-SMAC (Vgene, USA) overexpressing 
H1299, and H460 cells in response to vehicle or PD 0332991 were measured by 
Dichlorofluorescin fluorescence. Briefly, 1×106cells were treated with DCFDA (1μM) and 
incubated for 30 min in dark at 37°C. At the end of incubation, cells were washed once and 
re-suspended in phosphate buffered saline. DCF fluorescence was measured using 100μl of 
cell suspension in a plate reader at excitation 525 nm and emission at 575 nm (8).
Cellular Toxicity and Cell Viability Analysis
shCon or shRB or or shFOXM1 or shSMAC or Adeno Flag-SMAC were exposed to various 
conditions (Vehicle, PD 0332991, cisplatin (20 μM), 2Gy ionizing radiation [Pantak radiator, 
Thomas Jefferson University], or combination thereof) as indicated. Viable cells were 
counted using trypan blue exclusion assay.
Mapping of RB/E2F binding sites on FOXM1, Survivin/BIRC5, PCNA, and CyclinA2 
Promotor and Chromatin Immunoprecipitation Assay
1KB human RHAMM promoter was analyzed putatively for transcription factor binding 
sites using bioinformatics tools and programs, including Match-Public (www.gene-
regulation.com/cgi-bin/pub/programs/match/match.cgi), AliBaba2 (wwwiti.cs.uni-
magdeburg.de/∼grabe/alibaba2), and transcription Element Search software that utilizes the 
Transcription Factor Database (bioinformer.ebi.ac.uk:80/newsletter/archives/2/tess.html). 
The affinity of RB on FOXM1 or BIRC5 or CCNA2, or PCNA promoters were determined 
by ChIP assay as described (5). Briefly, RB-proficient and RB-deficient H1299 or H460 
cells were treated overnight with PD 0332991 (500 nM), cross-linked with formaldehyde 
and processed for chromatin immunoprecipitation analysis as described. Equal 
concentrations of chromatin from all treatment groups were pre-cleared with protein G or 
Protein A Dynabeads in the presence of bovine serum albumin to reduce the non-specific 
background. After removal of beads by centrifugation, 2 micrograms of RB antibody or 
ACH4 (BD Sciences, USA. Cell Signaling, USA) was added and kept overnight at 4°C on a 
rotary platform. The immunoprecipitated DNA was purified using PCR purification kit 
(Qiagen, Valencia, CA) and suspended in 50 μl of sterile water. Purified DNA was then 
amplified via semi- or real-time quantitative PCR to analyze RB bound on to the promoters 
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of FOXM1, Survivin/BIRC5, CyclinA or PCNA promoters with their respective target 
primers. The primer sequences are presented in Supplemental Table 1.
Input DNA served as a positive control whereas mouse IgG, or rabbit mouse monoclonal 
anti-GFP served as a negative control. PCR amplified products were resolved on agarose gel, 
and the images were captured using BioRad HemiDoc Imager (BioRad Laboratories, 
Hercules, CA). All real-time PCR analysis was performed with SYBR Green in a StepOne 
Plus PCR Thermocycler (Applied Biosystems). The signals were normalized with respective 
IgG or input signals and quantitated using ΔΔCt values as described (5).
Docking of E2F with FOXM1, Survivin/BIRC5, CyclinA, and PCNA promoters
The potential RB/E2F transcription factor binding sites on FOXM1, Survivin/BIRC5, 
CyclinA, or PCNA promoter DNA binding site were modeled under program coot (8) using 
the crystal structure of an E2F4-DP2-DNA complex as a template (9). The resultant model 
was subjected to iterative energy minimization routines using macromolecular docking 
program HEX (10) to generate 15 docking models with low interaction energies and clash-
free spatial conformations. The model with lowest interaction energy is displayed using 
molecular viewer program PyMOL.
β-Galactosidase Assay
Briefly, shCon, shRB H1299 and H460 cells were grown in the presence of DMSO or 
PD-0332991 (500 nM) for two weeks and were processed for β-galactosidase activity as 
described earlier. Staining was carried out according to manufacturers provided protocol 
(Cell Signaling Technology). β-Galactosidase-positive cells were scored and calculated as a 
percentage of total cell population.
In silico TCGA Analysis
RB1 GISTIC putative copy number estimates and mRNA RSEM expression estimates of 
selected target genes were obtained from the cBioPortal for Cancer Genomics using the 
MATLAB CGDS Cancer Genomics Tool box (1,11). Both RB1 GISTIC copy number 
estimates and RSEM mRNA expression values were available for 512 lung adenocarcinoma 
cases, and both were available for 501 lung squamous cell carcinoma cases. Box plots were 
created for select target gene mRNA expression as a function of RB1 GISTIC copy number 
score (including −2: homozygous loss, −1: heterozygous loss, 0: normal diploid, and ≤+1: 
copy gain). Differential expression p-values between the copy-number states were estimated 
using one-way ANOVA.
Mouse Xenograft and Immunohistochemistry
Mouse Xenografts were generated as described previously. RB-proficient or RB-deficient 
H1299 or H460 cells at a concentration of 2×106 or 5×105 were individually mixed (1:1) 
with matrigel in a 200μL volume (BD Biosciences), and then implanted subcutaneously into 
the flanks of 4- to 6-week-old female nude mice (Taconic, USA). Tumor growth was 
measured periodically using calipers or the IVIS imaging system with RediJect D-Luciferin 
as described (12). Once the tumors reached 100-120 mm3 volumes, animals were given PD 
0332991 (150 mg/kg body weight in sodium lactate buffer, pH 4.0) or vehicle daily via oral 
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gavage. Three weeks post PD 0332991 treatment for H1299 tumor bearing animals or 15 
days for H460 tumor bearing animals were euthanized, tumors were excised, imaged and 
fixed in 10% neutral buffered formalin for 24 h followed by 70% ethanol and were then 
embedded in paraffin. All animal experiments were conducted in accordance with the NIH 
Guide for Care and Use of Laboratory Animals and were approved by the Thomas Jefferson 
University Institutional Animal Care and Use Committee. Xenografts were analyzed for 
pRBS780, PCNA, MCM7 and LaminB. IHC analysis was carried out as described in (5). 
Paraffin embed shCon H1299 or shRB H1299 induced tumor xenografts were sectioned and 
stained for H&E. Tissue sections were scanned on a ScanScope™ XT, with an average scan 
time of 120 seconds (compression quality 70). For the nuclear analysis, the total area 
obtained from the cellblock was analyzed counting the number of cells, the average nuclear 
size, the cellularity ratio (cell count/area) and the intensity of the nuclear stain. For the 
cytoplasmic analysis areas of staining were color separated from hematoxylin counter-
stained sections and the intensity of the staining was measured on a continuous 0 (black) to 
255 (bright white) intensity scale.
Statistics
Statistical analyses were performed using GraphPad Prism (version 6.0) software (GraphPad 
PrismSoftware, Inc). All the data were analyzed for statistical significance using Student’s t-
test/ one-way ANOVA. For all experiments, p < 0.05 was considered statistically significant.
Results
Activated RB Inhibits Cell Cycle Progression
The retinoblastoma tumor suppressor is altered in 4-30% of non-small cell lung cancers 
(1,11). In order to delineate the functional impact of RB loss, two isogenic cell lines (H1299 
and H460) with stable knockdown of RB were generated. Genetically, these lines are distinct 
in that H1299 has homozygous deletion of p53 and wildtype KRAS, whereas H460 harbors 
mutant KRAS. RB knockdown was confirmed by mRNA and protein analysis (Figure 1A). 
Loss of RB allows E2F transcription factors to bind to promoters facilitating a 
transcriptional program, which enables G1/S cell cycle progression. The functional 
consequence of RB loss was verified using two established RB/E2F targets, CyclinA and 
PCNA. As compared to RB proficient cells, RB deficient cells demonstrated elevated basal 
transcripts (Figure 1B) and protein levels (Figure 1C) of CyclinA and PCNA. Further, 
activation of RB, via CDK4/6 inhibition, resulted in suppression of these targets in an RB-
dependent manner (Figure 1B and C). CDK4/6 inhibition triggered hypophosphorylation of 
RB protein (pRB) as compared to vehicle treatment (Figure 1C).
To ensure that repression of CyclinA and PCNA expression were mediated via canonical 
RB /E2F function, the RB-E2F consensus binding sites on their respective promoters were 
identified (Supplemental Figure 1A). Further chromatin immunoprecipitation indicated that 
upon CDK4/6 inhibition, RB binds robustly on the CyclinA and PCNA promoter sites with 
concurrent deacetylation of histone 4 (Supplemental Figure 1B), indicating that RB binding 
results in a closed chromatin state that represses cyclin A and PCNA transcription. 
Conversely, no binding was detected in the context of RB loss. Binding affinities on the 
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promoters were further confirmed through an in silico-docking model (Supplemental Figure 
1C). Interestingly, RB status did not alter cell cycle under basal conditions as measured by 
pulsed BrdU incorporation, however, exposure to the CDK4/6 inhibitor significantly reduced 
the proportion of cells within S-phase in the RB proficient setting only (Figure 1D). This 
translated into a statistically significant RB-dependent decrease of in vitro cell growth in 
both NSCLC (H1299 and H460) cell lines when exposed to a CDK 4/6 inhibitor (Figure 
1E).
CDK4/6 Inhibition Restricts Tumor Growth and Tumor Burden
RB-proficient and RB-deficient luciferase expressing H1299 and H460 cells were implanted 
into nude mice. Upon reaching 100-120 mm3, CDK4/6 inhibitor, (palbociclib) was 
administrated orally for 21 days as per the FDA clinical indication. Weekly luciferase 
assessment of tumor growth demonstrated that CDK4/6 inhibition significantly reduced 
tumor burden in RB-proficient tumors, but did not impact growth on RB-deficient tumors 
(Figure 1F, top panel, Supplemental Figures 1D, 1E top panel, and 1F). In vivo tumor 
volume and mass correlated with luciferase activity (Figure 1F, bottom panel, Supplemental 
Figure 1E bottom panel). Xenografts were harvested and analyzed for RB phosphorylation 
status and RB target genes; protein analysis demonstrate that RB was activated via 
hypophosphorylation resulting in repression of RB/E2F target genes MCM7 and PCNA in 
RB-proficient tumors (Figure 1G, Supplemental Figure 1G) with no change in either CDK4 
or CDK6 protein levels. These results demonstrate that CDK4/6 inhibition restricts the cell 
cycle in an RB-dependent manner and resulting in decreased tumor burden.
RB-Induced Cellular Senescence
Recent investigations have provided provocative evidence that CDK4/6 inhibition can trigger 
irreversible cell cycle withdrawal, a state referred to as senescence (13). To investigate 
whether CDK4/6 inhibition induced cellular senescence was dependent on functional RB, 
RB-proficient and RB-deficient H1299 and H460 cells were exposed to PD 0332991 for two 
weeks and analyzed for the expression of the senescence marker β-galactosidase activity. 
Interestingly, elevated levels of β-galactosidase activity were observed in RB-proficient cells 
in response to PD 0332991, while RB-deficient cells failed to induce β-galactosidase, 
suggesting an RB-dependent senescence program (Supplemental Figure 2A). Microarray 
data derived from RB-proficient H1299 cells under vehicle and CDK4/6 inhibitor (PD 
0332991) treated conditions were subjected to Ingenuity Pathway Analysis (IPA) pathway 
analysis and PD 0332991 treated cells demonstrated an enhanced cellular senescence via 
differentially regulated gene signatures (Supplemental Figure 2B). Further, Gene Set 
Enrichment Analysis (GSEA) of array data indicates de-enrichment of senescence-related 
gene sets contained within the Molecular Signatures Database (MSigDB) (Supplemental 
Figure 2B, left and right panel). The network demonstrates that senescence involved 
signature interactions (Supplemental Figure 2C). These findings confirm that RB is a key 
regulator of cellular senescence in NSCLC and may result in the RB-dependent inhibition of 
cellular growth.
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CDK 4/6 Inhibition Impacts on Cellular Apoptosis
Immunohistochemical analysis of tumor sections revealed an unexpected finding; an 
apoptotic as opposed to senescent mechanism for RB-dependent tumor inhibition. The role 
of RB in promoting or inhibiting apoptosis depends considerably on the context and 
apoptotic cues (14). While, RB-proficient cells treated with vehicle (Figure 2A) showed 
clear mitotic figures, those cells exposed to the CDK4/6 inhibitor exhibited smaller cell 
membranes with wrinkled nuclei; a hallmark of apoptosis. In contrast, RB-deficient tumors, 
regardless of treatment condition, maintained mitotic figures, indicating that the apoptotic 
response to CDK 4/6 inhibition in the context of NSCLC is an RB-dependent process 
(Figure 2A). To further validate that apoptosis was a driving mechanism within this system, 
RB-proficient and RB-deficient xenografts exposed to CDK4/6 inhibitor were analyzed for 
apoptotic protein markers cytochrome C and cleaved caspase 3. Only RB-proficient 
xenografts treated with the CDK 4/6 inhibitor expressed high levels of cytochrome C and 
cleaved caspase 3 (Figure 2B). In addition, RB specificity was demonstrated using a 
cytoplasmic histone-associated DNA fragments after induced cell death immunoassay 
(Figure 2C). Concomittantly, elevated levels of p27, and Smac were observed (Figure 2D). 
Given that apoptosis is a complex biological process, we performed a human apoptosis 
antibody array to determine which components of the apoptotic pathway were critical for 
CDK 4/6 inhibition induced apoptosis. We noted that the following cellular apoptosis 
markers SMAC, p27, HTRA, TNFR-1, and Caspase 3 were strongly induced following 
therapeutic challenge of RB proficient tumors with a CDK4/6 inhibitor in both NSCLC cell 
lines (Figure 2E). Confocal microscopy performed on RB-proficient H1299 and H460 cells 
exposed to CDK4/6 inhibitor illustrated pronounced fragmented (apoptotic) nuclei and 
fragmented F-actin; in contrast, RB-deficient H1299 and H460 cells displayed intact nuclei 
and active F-actin fibers (Supplemental Figure 3A). Apoptosis markers including SMAC, 
p27, HTRA, TNFR-1, and Caspase 3 were strongly induced following therapeutic challenge 
of RB proficient tumors with a CDK4/6 inhibitor in vitro (Supplemental Figure 3B and 3C). 
With induction of apoptosis, there was a concomitant increase in reactive oxygen species 
noted with CDK 4/6 inhibition in the RB proficient setting (Supplemental Figure 3D). An in 
silico analysis of human lung adeno carcinoma gene expression data revealed a direct 
correlation of the apoptotic marker TNFR-1 with RB1 copy number (Supplemental Figure 
3E). These collective findings nominate RB as a key modulator of CDK 4/6 inhibition 
induced cellular apoptosis in NSCLC.
SMAC Activation Promotes Cellular Apoptosis
Cellular apoptosis can be activated via either the extrinsic death receptor pathway or 
intrinsic mitochondrial pathway (15). Given the elevation of cytochrome C, a key factor in 
the mitochondrial pathway, when CDK4/6 inhibition was introduced into the RB proficient 
setting (Supplemental Figure 3B), we interrogated the role of SMAC, which was elevated on 
our array (Figure 2E, Supplemental 3C) and is induced with cytochrome C to release from 
the mitochondria (16) in mediating RB activated apoptosis. Protein analysis demonstrated 
that RB activation led to elevated cleaved caspase 3 via increased SMAC levels (Figure 3A). 
Generation of ectopic expression of Flag-SMAC increased cleaved caspase 3 in both in vitro 
NSCLC models (Figure 3B), repressed growth independent of RB status (Figure 3C, 
Supplemental 4A and 4B) and increased the ROS levels (Figure 3D). Interestingly, 
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knockdown of SMAC inhibited cleaved caspase 3 activation and Annexin V, despite 
CDK4/6 inhibitor treatment (Figure 3E, top panel, Supplemental 4C and D), increased the 
cell growth (Figure 3E, bottom panel, Supplemental 4C and D) and maintained cell viability 
despite genotoxic stress (Figure 3F and supplemental Figure 4E (top and bottom panel). 
Thus, SMAC is a critical mediator of RB-activated apoptosis.
Reactivated RB Represses IAPs (FOXM1 and Survivin/BIRC5) in NSCLC
As RB mediates its canonical function through inhibition of E2F target signatures (17–19), 
we utilized an unbiased genome wide microarray approach to examine which biological 
pathways and gene products are impinged on via CDK 4/6 inhibition. Pathway analysis of 
human transcriptome array via gene ontology identified that the apoptosis pathway genes 
were the most perturbed in the setting of CDK 4/6 inhibition (Figure 4A). Further, the top 
two inhibitors of apoptosis genes (IAPs), which were repressed via RB activation included 
FOXM1 and Survivin, which are key inhibitors of apoptosis proteins (IAPs) (Figure 4B, 
Supplemental 5A and B). FOXM1 and Survivin were validated by real time RT-PCR and 
protein analysis in RB proficient and deficient H1299 cells in response to the CDK4/6 
inhibitor (Figure 4C). In addition, an in-silico analysis of human lung cancer data revealed 
that RB copy number gain inversely correlated with the RB loss signature, FOXM1 and 
Survivin (Figure 4D) suggesting that RB is necessary to invoke apoptosis.
RB/E2F Governs FOXM1 and Survivin Transcription
RB/E2F complexes regulate transcription primarily by binding to promoter regions and 
altering chromatin structure (20). An in-silico analysis of RB/E2F putative binding sites 
within 1Kb of the FOXM1 and Survivin start site revealed several potential binding sites 
(Figure 5A). Binding affinities on the promoters were further confirmed through an in silico-
docking model (Supplemental Figure 5C). Further chromatin immunoprecipitation indicated 
that upon CDK4/6 inhibition, RB binds robustly on the RB/E2F site II (Figures 5B and C) 
with consonant deacetylation of histone 4 (Figures 5B and C) in both H1299 and H460 cells, 
indicating that RB binding results in a closed chromatin state that inhibits transcription. 
Conversely, no binding was detected in the context of RB loss. Furthermore, RB failed to 
associate with any other putative/predicted RB-E2F binding site. Ectopic expression of 
adenovirus harboring E2F1, E2F2, and E2F3 cDNAs demonstrated that inhibitor of 
apoptosis proteins FOXM1 and Survivin (IAPs) are RB/E2F regulated genes (Figure 5D). 
Thus, these results confirm that transcriptional regulation of these IAPs are mediated 
through the RB/E2F signaling cascade.
RB Activated Apoptosis is mediated via FOXM1/SURVIVIN-SMAC Balance
IAP family members contain baculoviral IAP repeat (BIR) domains capable of inhibiting 
caspases (21). Inhibition of FOXM1 or Survivin function was achieved through stable 
knockdown (Figure 6A, left panel). FOXM1 and Survivin are key regulators of cell cycle 
(Figure 6A, right panel) and proliferation (Figure 6B). Further, inhibition of FOXM1 and 
Survivin led to increased levels of reactive oxygen species (Figure 6C), mimicking the 
function of activated RB. SMAC is known to interact with IAPs via the BIR domain (22). In 
our models, FOXM1 physically interacts with both Survivin and Caspase 3 preventing 
cleavage of Caspase 3 and the downstream apoptotic pathway (Figure 6D). Overexpression 
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of either FOXM1 or Survivin inhibits the ability of palbociclib to alter cellular viability 
(Figure 6E and 6F). Interestingly, ectopic expression of Flag-SMAC enabled binding of 
SMAC with Caspase 3 and cleaved caspase (Figure 6G), yet did not perturb the interaction 
of FOXM1 and Survivin (Figure 6H). In summation, activated RB represses FOXM1 and 
Survivin expression with concurrent up-regulation of SMAC, leading to ROS generation and 
inducing cell death as shown in our working model (Supplemental Figure 6).
Discussion
The role of RB as a regulator of cell cycle and progression is well established (23), and 
numerous studies have established that pharmacologic inhibition of the CDK4/6 complex 
results in cell cycle arrest through activation of RB (24–29). Recently, RB has been 
recognized to function in many other key biological processes including apoptosis (30). RB 
has been demonstrated to either promote or inhibit apoptosis depending on the context, 
apoptotic cues and its own functional status. In the current study, we discovered for the first 
time a novel apoptotic role of RB beyond its transcriptional regulatory function. Our data 
strongly support the hypothesis that CDK4/6 inhibition activates the RB pathway and 
orchestrates cellular apoptosis through repression of IAPs and subsequent enhancement of 
pro-apoptotic signaling via SMAC and cleaved Caspase 3. This conclusion is supported by 
several key findings 1) Activated RB via CDK4/6 inhibition represses cellular proliferation 
and tumor burden in vivo; 2) induces cellular apoptosis and production of reactive oxygen 
species; 3) drastically activates/stabilizes pro-apoptotic mitochondrial proteins SMAC, 
Cytochrome C, HTRA, p27, TNFR-1; 4) suppresses transcription of FOXM1 and Survivin 
through promoter binding thus allowing SMAC to cleave Caspase 3. Based on these 
discoveries, we propose a novel role for CDK4/6 inhibitors in management of RB-proficient 
NSCLC and an important role of the RB/E2F signaling outside of canonical transcriptional 
control.
Apoptosis is often accompanied by a shift from the hyperphosphorylated (inactive) to the 
hypophosphorylated form of RB (31). Phosphatase activity directed toward RB appears to be 
necessary for induction of apoptosis in different cancer types (32–34), while RB 
hyperphosphorylation is linked to resistance to apoptotic therapy (35,36). Studies in 
promyelocytic leukemia and breast cancer suggest that dephosphorylation is required for 
caspase cleavage (37) and accumulation of the active hypophosphorylated form of RB 
triggers apoptosis (38) in the context of prostate cancer. Our study further supports the role 
of RB in promoting apoptosis whereby RB suppresses transcription of the IAP family 
members, FOXM1 and Survivin, while inducing SMAC.
SMAC is a mitochondrial protein that interacts with the Inhibitor of Apoptosis Proteins 
(IAPs) and upon apoptotic stimuli is released into the cytoplasm to inhibit IAP binding to 
caspase (39). SMAC binds to baculoviral IAP repeats (BIR), which directly prevents IAP-
caspase binding enabling apoptosis. While translocation of JNK from the cytosol to the 
mitochondria (40) and downregulation of c-Myc (41) have been demonstrated to cause 
release of SMAC from the mitochondria, our study is the first to implicate RB in mediating 
this process. We demonstrate that SMAC is a key regulator of activated RB induced 
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apoptosis, as SMAC knockdown prevented caspase cleavage despite presence of CDK4/6 
inhibition.
Our study demonstrates a new potential treatment paradigm for lung cancer, CDK4/6 
inhibitor monotherapy. Within the context of NSCLC, studies have demonstrated an 
antagonistic interaction of CDK4/6 inhibition and cisplatin response (42), however, in the 
setting of esophageal cancer, combination therapy was synergistic (43). This may be cell 
context dependent, perhaps reliant on the necessity of CDK4 vs. CDK6 function for 
different cancer types. Multiple combination trials with palbociclib, ribociclib, and 
abemaciclib are currently accruing; while findings may be generalizable within this class of 
agents, difference in patient response could be due to unique targeting of each agent to 
distinct kinases (44). Our study suggests efficacy of single agent use regardless of KRAS or 
p53 status. This is supported by reports that one patient, who had previously been treated 
with gefitinib, exhibited clinical remission after treatment with PD 0332991 (45). This 
demonstrates our study finding which implicates conversion of a presumed “cytostatic” 
agent into a cytotoxic therapeutic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
Lung cancer remains the most common cause of cancer related death in the United States 
despite recent advances in targeted agents and immunotherapy. We describe the 
preclinical efficacy of palbociclib (PD 0332991) in RB-proficient and deficient non-small 
cell lung cancer (NSCLC) when dosed per the current FDA-indication. Our study 
demonstrates that CDK 4/6 inhibition results in apoptosis specifically in RB-proficient 
models. This mechanism is mediated through upregulation of SMAC leading to cleaved 
Caspase 3 with concurrent repression of inhibitors of apoptosis: FOXM1 and Survivin. 
The novelty of our finding suggests that “cytostatic” drugs may have cytocidal properties 
with prolonged exposure positing a new therapeutic strategy in the management of 
patients with RB positive NSCLC.
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Figure 1. RB activation via CDK4/6 inhibition restricts NSCLC growth
(A) RB mRNA and RB immune blot analysis in RB proficient and deficient H1299 and 
H460 non small cell lung cancer (NSCLC) cells and the loading controls GAPDH mRNA 
and LaminB. (B) qRT-PCR analysis of E2F targets CyclinA and PCNA in RB proficient and 
deficient H1299 and H460 cells (C) Immunoblot analysis of ppRB, S780, pRB, CyclinA, 
PCNA and a loading control LaminB in RB proficient and deficient H1299 and H460 cells. 
(D) Flow cytometric analysis of BrdU incorporation in RB proficient and deficient H1299 
and H460 cells in response CDK4/6 inhibitor (500 nM). (E) Graphic representation of 
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growth analysis in RB proficient and RB deficient H460 and H1299 (shCon and shRB) cells 
in response to CDK4/6 inhibitor (500 nM) for 12 days in culture. (F) Graphic representation 
(top panel) of IVIS derived tumor luminescence of shCon and shRB H1299 cell line induced 
xenografts in response to CDK4/6 inhibition (150mg/kg body wt) and a graphic 
representation of tumor volume and tumor mass of shCon and shRB H1299 cell line induced 
xenografts (bottom panel) in response to CDK4/6 inhibition for three weeks (150mg/kg 
body wt). (G) Immunoblotting analysis of pRB, ppRBS780, LaminB, MCM7, PCNA, 
CDK4, CDK6, p16 and GAPDH loading control in shCon and shRB H1299 xenografts in 
response to CDK4/6 inhibition for three weeks (150mg/kg body wt). Each data point is a 
mean ± SD 5 or more animals or three or more independent experiments. **p <0.05 were 
considered as statistically significant.
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Figure 2. RB Promotes In Vivo Cellular Apoptosis in NSCLC
(A) H&E staining of shCon and shRB H1299 and H460 cell line induced xenografts (400×) 
in response to CDK4/6 inhibition (150 mg/kg body wt) and a graphic representation of 
apoptosis positive nuclei in RB proficient and deficient H1299 and H460 cell line induced 
xenografts in response to CDK4/6 inhibition (left and right panel). (B) Immunoblotting 
analysis of cytochrome C, Cleaved caspase3 and LaminB in shCon and shRB H1299 cell 
line induced xenografts in response to CDK4/6 inhibition (150 mg/kg body wt) and a 
graphic representation of cytochrome C and cleaved caspase 3 expression in shCon and 
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shRB tumor lysates. (C) Graphic representation of cell death analysis via photometric 
enzyme immunoassay in shCon and shRB H1299 cells in response to CDK4/6 inhibition 
(150-mg/kg body wt). (D). Immunoblotting analysis of p27, Smac Cytochrome c, cleaved 
caspase 3 and GAPD in shCon and shRB H460 xenograft in response to CDK4/6 inhibitor 
(150 mg/kg body weight). (E) Apoptotic array (protein array) images from shCon and shRB 
H1299 cells induced xenografts in response CDK4/6 inhibition (150-mg/kg body wt) and a 
graphic representation of apoptotic markers and a graphic representation of Caspase3, 
HTRA, p27, Smac and TNFR-1 expression in shCon and shRB tumor lysates. In each group 
5 or more animals were used and each data point is a mean ± SD from 5 or more animals or 
three or more independent experiments. **p <0.05 were considered as statistically 
significant.
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Figure 3. Mitochondrial protein SMAC regulates NSCLC apoptosis
(A) Immunoblotting analysis of SMAC, cleaved caspase 3 and a loading control LaminB in 
RB proficient and RB deficient H1299 and H460 cells (shCon and shRB) in response to PD 
0332991 (500 nM). (B) Immunoblotting analysis of SMAC, cleaved caspase 3 and a loading 
control LaminB in control and SMAC overexpressing H1299 and H460 cells. (C) A graphic 
representation of cell growth analysis in control and SMAC overexpressing H1299 and 
H460 cells. (D) A graphic representation of ROS (reactive oxygen species) analysis in 
control and SMAC overexpressing shCon and shRB H1299 and H460 cells. (E) 
Thangavel et al. Page 21
Clin Cancer Res. Author manuscript; available in PMC 2019 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Immunoblotting analysis of cleaved caspase 3, SMAC, PCNA, annexin V and a loading 
control GAPDH in SMAC proficient (shCon) and SMAC deficient (shSMAC) in H1299 
cells (top panel) and a graphic representation of cell growth in SMAC proficient (shCon) and 
SMAC deficient (shSMAC) in H1299 cells (bottom panel) in response to PD 0332991 (500 
nM). (F) A graphic representation of cell viability in SMAC proficient (shCon) and SMAC 
deficient (shSMAC) in H1299 cells in response to cisplatin (20 μM) or radiation (2Gy) or a 
combination of cisplatin and radiation. Each data point is a mean ± SD from three or more 
independent experiments. **p <0.05 were considered as statistically significant.
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Figure 4. Transcriptome Array Profiling and Identification RB/E2F Targets (FOXM1 and 
Survivin) in NSCLC
(A) Gene ontology analysis in H1299 microarray data via IPA software in response to 
CDK4/6 inhibition for 21 days. (B) Microarray analysis derived RB/E2F signatures involved 
in apoptosis signaling. (C) qRT-PCR and protein validation of FOXM1, Survivin in H1299 
cells in response to CDK4/6 inhibition for 21 days. (D) In silico analysis and box plot 
representation of RB loss signatures, FOXM1 and Survivin transcript expression in relation 
to RB copy number in human lung adenocarcinoma. Each data point is a mean ± SD from 
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three or more independent experiments. **p <0.05 were considered as statistically 
significant.
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Figure 5. RB Mediates FOXM1 and Survivin Transcription in NSCLC
(A) Schematic illustration shows the location of three putative RB/E2F binding sites on 
FOXM1 and Survivin upstream sequence (promoters). (B & C left panels) Real-time PCR 
analysis of α-RB Chromatin immunoprecipitation assay shows the recruitment of RB on 
RB/E2F binding site II on FOXM1 and Survivin promoter, mouse α-GFP served as a 
negative control and input served as a positive control in shCon and shRB H1299 cells in 
response CDK4/6 inhibition (500 nM). (B & C right panels) PCR analysis of α-ACH4 
chromatin immunoprecipitation assay shows that RB fails to recruit on RB/E2F binding site 
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II on acetylated FOXM1 and Survivin promoter. Rabbit IgG served as a negative control and 
input served as a positive control in shCon and shRB cells in response to CDK4/6 inhibition 
(500 nM). (D) Immunoblotting analysis of FOXM1 Survivin, E2F1, E2F2, E2F3 and 
LaminB in ectopically expressed adenovirus harboring E2F1, E2F2, E2F3 cDNA in H1299 
and H460 cells. Each data point is a mean ± SD from three or more independent 
experiments. **p <0.05 were considered as statistically significant.
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Figure 6. Genetic ablation of FOXM1 and Survivin negatively regulates NSCLC apoptosis via 
caspase 3 interactions
(A) Immunoblotting analysis of FOXM1, Survivin and a loading control in FOXM1 and 
Survivin proficient and deficient H1299 and H460 cells (left panel) and a flow cytometric 
analysis of BrdU incorporation in FOXM1 and Survivin proficient and deficient H1299 and 
H460 cells (right panel). (B) A graphic representation of cell survival analysis in FOXM1 
and Survivin proficient and deficient H1299 and H460 cells (left and right panel). (C) A 
graphic representation of ROS (reactive oxygen species) analysis in FOXM1 and Survivin 
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proficient and deficient H1299 and H460 cells (left and right panel). (D) Co-
immunoprecipitation of FOXM1 and immune blotting analysis of FOXM1, Survivin and 
Caspase3 and a GAPDH loading control in shRB H1299 cells. (E) A graphic representation 
of cell viability analysis in FOXM1 overexpressing H1299 and H460 cells in response to PD 
0332991 (left and right panel) (F) A graphic representation of cell viability analysis in 
Survivin overexpressing H1299 and H460 cells (left and right panel). (G) Co-
immunoprecipitation of SMAC and immunoblotting analysis of FOXM1, Survivin, SMAC, 
Caspase 3, Cleaved Caspase3 and LaminB loading control in SMAC overexpressing shRB 
H1299 and H460 cells. (H) Co-immunoprecipitation of FOXM1 and immunoblotting 
analysis of FOXM1, Survivin and SMAC in SMAC overexpressing shRB H1299 and H460 
cells. Each data point is a mean ± SD from three more independent experiments. **p <0.05 
were considered as statistically significant.
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